Barclays
PGNX

Barclays’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Barclays’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-25,500
Closed -$97K – 6539
2020
Q1 		$97K Sell
25,500
-2,100
-8% -$9.05K ﹤0.01% 4829
2019
Q4 		$140K Buy
27,600
+6,000
+28% +$31.7K ﹤0.01% 5280
2019
Q3 		$109K Buy
21,600
+3,600
+20% +$18K ﹤0.01% 5420
2019
Q2 		$111K Buy
18,000
+7,500
+71% +$36.2K ﹤0.01% 5604
2019
Q1 		$49K Sell
10,500
-79,800
-88% -$361K ﹤0.01% 5890
2018
Q4 		$379K Buy
90,300
+7,100
+9% +$36.1K ﹤0.01% 4066
2018
Q3 		$522K Buy
83,200
+8,300
+11% +$63.8K ﹤0.01% 4240
2018
Q2 		$602K Sell
74,900
-11,900
-14% -$90.8K ﹤0.01% 3773
2018
Q1 		$648K Buy
86,800
+6,600
+8% +$43.9K ﹤0.01% 3697
2017
Q4 		$477K Buy
80,200
+7,300
+10% +$44.4K ﹤0.01% 3881
2017
Q3 		$537K Sell
72,900
-3,700
-5% -$23.5K ﹤0.01% 3558
2017
Q2 		$520K Buy
76,600
+45,000
+142% +$332K ﹤0.01% 3484
2017
Q1 		$298K Buy
31,600
+11,300
+56% +$113K ﹤0.01% 3932
2016
Q4 		$175K Buy
20,300
+10,200
+101% +$75.4K ﹤0.01% 4315
2016
Q3 		$64K Buy
10,100
+9,300
+1,163% +$56.2K ﹤0.01% 4838
2016
Q2 		$3K Buy
800
+600
+300% +$2.9K ﹤0.01% 5888
2016
Q1 		$1K Buy
+200
New +$891 ﹤0.01% 6050
2015
Q4 		– Sell
-400
Closed -$2K – 6848
2015
Q3 		$2K Sell
400
-2,600
-87% -$20K ﹤0.01% 6423
2015
Q2 		$21K Sell
3,000
-2,600
-46% -$15.7K ﹤0.01% 5662
2015
Q1 		$28K Sell
5,600
-8,600
-61% -$54.1K ﹤0.01% 5660
2014
Q4 		$99K Buy
14,200
+3,000
+27% +$17.9K ﹤0.01% 5214
2014
Q3 		$56K Sell
11,200
-4,700
-30% -$23.4K ﹤0.01% 5795
2014
Q2 		$64K Buy
15,900
+6,500
+69% +$24.8K ﹤0.01% 5772
2014
Q1 		$38K Buy
9,400
+8,300
+755% +$42.4K ﹤0.01% 6219
2013
Q4 		$6K Buy
1,100
+1,000
+1,000% +$4.4K ﹤0.01% 7151
2013
Q3 		$1K Sell
100
-7,700
-99% -$41.8K ﹤0.01% 7329
2013
Q2 		$35K Buy
+7,800
New +$35K ﹤0.01% 6546

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Barclays's PGNX Position: Q2 2020 in Review

Barclays sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 73,821 shares — an estimated $280K sold.

Barclays first reported a position in PGNX in Q2 2013 and held it in 27 quarters. The position peaked at $2.12M in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Barclays reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Barclays sold 73,821 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $280K.
  • Barclays first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 27 quarters.
  • Barclays's Progenics Pharmaceuticals Inc position peaked at $2.12M in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.